·Category 1 new drug ·The world's first CDK2/4/6 inhibitor, indicated for use in combination with fulvestrant for patients with HR+/HER2- locally advanced or metastatic breast cancer who have previously received endocrine therapy ·It provides a novel treatment option for addressing clinical CDK4/6 inhibitor resistance and alleviating myelosuppression

*For contraindications and adverse reactions, please see the package insert

·The first generic version worldwide, approved by three major regulatory authorities in China, the United States and the European Union ·It achieved a successful patent challenge and obtained a 12-month market exclusivity period in the Chinese market

*For contraindications and adverse reactions, please see the package insert